Claims

1. Use of paroxetine in the manufacture of a unit dose medicament for the treatment of a thermoregulatory dysfunction, wherein said unit dose is 7.5 mg, based on the paroxetine moiety.

2. Use according to claim 1, wherein said thermoregulatory dysfunction is the result of a condition selected from female menopausal related hormonal changes, male menopausal related hormonal changes, chemically induced hormonal changes, surgically induced hormonal changes, hormonal disruption disease states, and any combination thereof.

3. Use according to claim 1, wherein said thermoregulatory dysfunction is a condition selected from the group consisting of hot flushes, night sweats and combinations thereof.

4. Use according to claim 1, wherein the paroxetine comprises paroxetine free base.

5. Use according to claim 1, wherein the paroxetine comprises a pharmaceutically acceptable salt of paroxetine.

6. Use according to claim 5, wherein the pharmaceutically acceptable salt of paroxetine comprises paroxetine hydrochloride.

7. Use according to claim 5, wherein the pharmaceutically acceptable salt of paroxetine comprises paroxetine mesylate.

8. Use according to claim 1, wherein the paroxetine is in a crystalline form.

9. Use according to claim 1, wherein the paroxetine is in an amorphus form.

Claims

1. A method for treating a patient suffering from a thermoregulatory dysfunction comprising administering to said patient a compound selected from paroxetine, a pharmaceutically acceptable salt thereof, a hydrate or solvate of either, in any polymorphic form, and mixtures thereof; said compound being in an amount, based on the paroxetine moiety, which is at least about 0.1 mg/day up to less than a therapeutically effective antidepressant dosage of paroxetine.

2. The method of claim 1 wherein said compound is administered in an amount of at least 0.5 mg/day.

3. The method of claim 1 wherein said compound is administered in an amount of at least 1 mg/day.

4. The method of claim 1 wherein said compound is administered in an amount of at least 2 mg/day.

5. The method of claim 1 wherein said compound is administered in an amount of at least 4 mg/day.

6. The method of claim 1 wherein said compound is administered in an amount of not more than about 9.5 mg/day.

7. The method of claim 1 wherein said compound is administered in an amount of not more than about 9 mg/day.

8. The method of claim 1 wherein said compound is administered in an amount of not more than about 8.5 mg/day.

9. The method of claim 1 wherein said compound is administered in an amount of not more than about 8 mg/day.

10. The method of claim 1 wherein said compound is administered in an amount selected from 2 mg/day, 2.5 mg/day, 3 mg/day, 3.5 mg/day, 4 mg/day, 4.5 mg/day, 5 mg/day, 5.5 mg/day, 6 mg/day, 6.5 mg/day, 7 mg/day, 7.5 mg/day, 8 mg/day, and 8.5 mg/day.

11. The method of claim 1 wherein said thermoregulatory dysfunction is the result of a condition selected from female menopausal related hormonal changes, male menopausal related hormonal changes, chemically induced hormonal changes,

surgically induced hormonal changes, hormonal disruption disease states, and any combination thereof.

12. The method of claim 1 wherein said thermoregulatory dysfunction is a condition selected from the group consisting of hot flashes, hot flushes, night sweats and combinations thereof.